ALDH Inhibitor Compounds for Cancer Treatment
Summary
The European Patent Office published patent application EP4326696A1 for N-(2-oxo-3,4-dihydro-1H-quinolin-6-yl)-pyridine-4-carboxamide derivatives as ALDH inhibitors for cancer treatment. Filed by Kayothera Inc. and The Trustees of Princeton University, the patent covers compounds with potential applications in oncology, metabolic disorders, and cardiovascular disease. The publication covers 37 designated European states.
What changed
The EPO published patent application EP4326696A1 for novel N-(2-oxo-3,4-dihydro-1H-quinolin-6-yl)-pyridine-4-carboxamide derivatives as ALDH (aldehyde dehydrogenase) inhibitors. The application, filed by Kayothera Inc. and Princeton University, covers compounds designated for cancer treatment (A61P 35/00) with additional therapeutic indications including metabolic disorders (A61P 3/00, 3/10) and cardiovascular conditions (A61P 9/12). The patent is classified under multiple C07D heterocyclic compound categories.
For pharmaceutical companies and researchers, this publication establishes priority date and public notice of the patent claims. Companies developing ALDH-targeted therapies or working in quinoline-carboxamide chemistry should review the claims for potential licensing needs, freedom-to-operate analysis, or competitive differentiation. The designated states cover major European markets including Germany, France, UK, Italy, Spain, Netherlands, and 29 additional countries.
What to do next
- Review patent claims for potential licensing or infringement concerns if developing ALDH-targeted cancer therapies
- Assess freedom-to-operate for any quinoline-carboxamide derivative programs
- Evaluate potential licensing opportunities from Kayothera/Princeton for therapeutic development
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
N-(2-OXO-3,4-DIHYDRO-1H-QUINOLIN-6-YL)-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AS ALDH INHIBITORS FOR THE TREATMENT OF CANCER
Publication EP4326696A1 Kind: A1 Mar 25, 2026
Applicants
Kayothera Inc., The Trustees of Princeton University
Inventors
ESPOSITO, Mark, PROUDFOOT, John, KANG, Yibin, PIWINSKI, John
IPC Classifications
C07D 215/38 20060101AFI20251211BHEP C07D 221/04 20060101ALI20251211BHEP C07D 401/12 20060101ALI20251211BHEP C07D 405/12 20060101ALI20251211BHEP C07D 405/14 20060101ALI20251211BHEP C07D 413/12 20060101ALI20251211BHEP C07D 417/12 20060101ALI20251211BHEP C07D 471/04 20060101ALI20251211BHEP C07D 491/048 20060101ALI20251211BHEP C07D 498/04 20060101ALI20251211BHEP C07D 513/04 20060101ALI20251211BHEP A61K 31/4704 20060101ALI20251211BHEP A61P 35/00 20060101ALI20251211BHEP A61P 3/00 20060101ALI20251211BHEP A61P 3/10 20060101ALI20251211BHEP A61P 9/12 20060101ALI20251211BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.